Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,511,320 papers from all fields of science
Search
Sign In
Create Free Account
caplacizumab
A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet and anti-thrombotic activities. Upon administration…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
ALX-0081
Broader (1)
Single-Domain Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PB2249 CAPLACIZUMAB MODEL-BASED DOSING RECOMMENDATIONS IN PEDIATRIC PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
L. Sargentini
,
E. Hansson
,
M. Bergstrand
,
F. Callewaert
,
R. Sousa
HemaSphere
2019
Corpus ID: 196522926
2018
2018
Ictus menor en una paciente con trombocitopenia
A. Gómez
,
A. García-Torres
,
+8 authors
G. Vega
2018
Corpus ID: 81312948
La purpura trombocitopenica trombotica es una enfermedad hematologica caracterizada por la formacion de trombos plaquetarios en…
Expand
2018
2018
Diagnosis and Management of Thrombotic Thrombocytopenic Purpura
N. Hamed
2018
Corpus ID: 140083094
TTP is a rare life-threatening disease resulting from absence of functional ADAMTS13. Aggregates of ultralarge vWF multimers…
Expand
2018
2018
Caplacizumab approved in Europe to treat aTTP
Jennifer Smith
2018
Corpus ID: 216821680
2016
2016
Caplacizumab. Anti-von Willebrand factor, Treatment of acquired thrombotic thrombocytopenic purpura
K. Haddley
2016
Corpus ID: 78396293